11 Most Promising Penny Stocks According to Analysts

5. Geron Corp. (NASDAQ:GERN)

Share Price as of April 15: $1.32

Number of Hedge Fund Holders: 46

Average Upside Potential as of April 15: 240.91%

Geron Corp. (NASDAQ:GERN) is a commercial-stage biopharmaceutical company that develops therapeutics for oncology. It offers RYTELO, which is a telomerase inhibitor for the treatment of adult patients with low to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS) with transfusion-dependent anemia. RYTELO was approved in the US in June 2024.

Later in August 2024, RYTELO also gained favorable placement in the NCCN guidelines and received a Category 1 treatment recommendation for second-line RS-positive and RS-negative patients. Since its launch in the US, RYTELO made $76.5 million in net product revenue by year-end. In Q4 2024 alone, RYTELO made $47.5 million in net product revenue.

RYTELO has received a positive opinion in Europe, with a final EU approval decision expected in H1 2025. This will potentially lead to a 2026 EU launch. On March 12, Wedbush analyst Robert Driscoll maintained a Buy rating on the stock with a $7 price target. Payers that cover about 80% of US-insured lives have favorable coverage for RYTELO. The US market for eligible lower-risk MDS patients is estimated to be ~15,400 in 2025.

ClearBridge Small Cap Growth Strategy stated the following regarding Geron Corporation (NASDAQ:GERN) in its Q1 2025 investor letter:

“We continued to generate a number of compelling new ideas, adding five new investments that we still held at quarter end: Glaukos, Rocket Lab USA, Karman Holdings (through its IPO), Archrock, Hims & Hers and Geron Corporation (NASDAQ:GERN).

Geron is a biotechnology company with a commercialized drug launching to treat blood cancer. Its product is newly entering a sizable market with broad applicability for patients who cycle through a variety of treatments throughout the course of the disease, allowing for a potentially larger revenue opportunity than currently appreciated by the market.”